RxDoctor Payments Data

Eugenio Guevara, MD

Neurology · Hialeah, FLNPI 1033305701

Payments from drug & device makers

$8,561in general payments, 2019–2025

Across 334 payments — averaging $25.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$3K
  • Neurocrine Biosciences, Inc.$1K
  • Acadia Pharmaceuticals Inc$1K
  • Adamas Pharmaceuticals, Inc.$654
  • Medtronic$515
  • Amneal Pharmaceuticals LLC$498
  • plus $2K from 14 others

What the payments were for

  • Speaking & faculty fees$691%
  • Travel & lodging$4385%
  • Food & beverage$8,02394%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,561 in reported general payments places this provider in the 60th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$92,807
Medicare patients
190
Services billed
860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate64$361,098
RytaryCarbidopa/Levodopa114$51,545
Levetiracetam ErLevetiracetam454$46,480
Lacosamide107$33,833
Memantine Hcl1,960$30,020
Carbidopa-Levodopa ErCarbidopa/Levodopa1,481$28,694
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,137$28,618
LyricaPregabalin36$27,862
Levetiracetam983$27,752
Carbidopa-LevodopaCarbidopa/Levodopa2,988$26,480
BriviactBrivaracetam64$26,466
Pregabalin449$18,544
FycompaPerampanel18$18,130
Ondansetron Hcl12$16,470
Rasagiline Mesylate58$16,171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$1,067$361,09864 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$498$60,751217 claims
PfizerLyrica$63$27,86236 claims
UCB, Inc.Briviact$2,643$26,46664 claims
Eisai Inc.Fycompa$314$18,13018 claims
Neurocrine Biosciences, Inc.Ongentys$1,218$11,21115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,434 neurology providers in Florida.

Other neurology in Hialeah

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →